Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options
Open Access
- 1 February 2012
- journal article
- review article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. 8, 77-89
- https://doi.org/10.2147/vhrm.s26030
Abstract
Peer reviewed article authored by (Fintel DJ). Read article or submit your manuscript for publishing.Keywords
This publication has 76 references indexed in Scilit:
- 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial InfarctionCirculation, 2011
- Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery diseaseEuropean Heart Journal, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsThe New England Journal of Medicine, 2009
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosisProceedings of the National Academy of Sciences of the United States of America, 2007
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002